Michael Barbella, Managing Editor01.05.24
Vensana Capital has launched a new company, Evident Vascular Inc., and bankrolled it with $35 million in Series A financing.
“The impetus to launch Evident Vascular was born out of the Vensana team’s experience in the vascular space. Our team has partnered with entrepreneurs across multiple emerging therapeutic categories in vascular disease over the last two decades, including endovascular aortic aneurysm grafts, drug-coated balloons, venous stents, arterial tacks, and thrombectomy devices,” Vensana Capital Managing Partner Justin Klein, M.D., said. “Intravascular ultrasound is ripe for innovation. Evident Vascular is addressing a critical need in the IVUS market, making it an ideal company to add to our vascular technology innovations.”
IVUS is a transcatheter intravascular imaging technique used to acquire images from inside blood vessels to evaluate vascular disease and guide interventional treatment. Although IVUS has steadily made inroads, predominantly in coronary interventions, clinical trial data supporting utilization in both coronary and peripheral interventions are fueling future market growth. Peripheral arterial and venous disease use is now the largest and fastest-growing segment of IVUS procedures in the United States.1,2,3
“While there have been significant advances in the options to treat peripheral vascular disease, the diagnostic tools needed to accurately and appropriately guide delivery of these therapies have lagged. We see a tremendous opportunity to create a next-generation IVUS platform that addresses the needs of vascular interventionalists, and we are excited to launch Evident Vascular,” Vensana Capital Principal Cynthia Yee stated.
“Legacy IVUS platforms were originally designed primarily for coronary procedures and secondarily for peripheral vascular applications. Shortcomings in image quality, interpretation, and workflow have limited the widespread adoption of IVUS despite its clinical benefit, and there has been minimal innovation to address these limitations,” Evident Vascular Co-Founder/CEO Howard Rosen said. “Along with my co-founders, Chief Technology Officer Patrick Phillips, Ph.D., and Chief Product Officer Danielo Piazza, our team is pioneering the future of intravascular imaging with a platform optimized for peripheral vascular procedures that will enable improved image interpretation guidance, and ease of use enhancements throughout the clinical workflow.”
Evident Vascular is developing an advanced intravascular ultrasound (IVUS) platform technology designed initially for peripheral vascular interventions, with future capability for coronary procedures. Leveraging artificial intelligence (AI) to enable superior image interpretation and streamlined workflows, Evident Vascular’s technology has been designed to expand adoption of IVUS, driving increased market penetration and enabling improved clinical outcomes with faster, more accurate diagnosis and treatment decisions.
Vensana Capital is a venture capital and growth equity investment firm launched in 2019. Vensana manages $550 million in capital and is actively investing in developing and commercial stage companies across the medtech sector, including medical devices, diagnostics and data science, life science tools, digital health, and tech-enabled services. Vensana's investment team has a history of successfully partnering with management teams behind such companies as Cameron Health, CardiAQ, Cartiva, CV Ingenuity, Epix Therapeutics, Inari Medical, Intact Vascular, Lutonix, Neuwave Medical, Personal Genome Diagnostics, Relievant Medsystems, Sequent Medical, Topera, Ulthera, Veran Medical Technologies, Vertiflex, and Vesper Medical.
References
1 Centers for Medicare & Medicaid Services (CMS). Public Use Files (Medicare Claims) - Medicare Physician & Other Practitioners - by Geography and Service 2013-2020. Accessed May 2023.
2 Centers for Medicare & Medicaid Services (CMS). Standard Analytical Files (Medicare Claims) - LDS 2021. Accessed May 2023.
3 Healthcare Cost and Utilization Project (HCUP) National Inpatient Sample - 2017-2020. Accessed September 2022.
“The impetus to launch Evident Vascular was born out of the Vensana team’s experience in the vascular space. Our team has partnered with entrepreneurs across multiple emerging therapeutic categories in vascular disease over the last two decades, including endovascular aortic aneurysm grafts, drug-coated balloons, venous stents, arterial tacks, and thrombectomy devices,” Vensana Capital Managing Partner Justin Klein, M.D., said. “Intravascular ultrasound is ripe for innovation. Evident Vascular is addressing a critical need in the IVUS market, making it an ideal company to add to our vascular technology innovations.”
IVUS is a transcatheter intravascular imaging technique used to acquire images from inside blood vessels to evaluate vascular disease and guide interventional treatment. Although IVUS has steadily made inroads, predominantly in coronary interventions, clinical trial data supporting utilization in both coronary and peripheral interventions are fueling future market growth. Peripheral arterial and venous disease use is now the largest and fastest-growing segment of IVUS procedures in the United States.1,2,3
“While there have been significant advances in the options to treat peripheral vascular disease, the diagnostic tools needed to accurately and appropriately guide delivery of these therapies have lagged. We see a tremendous opportunity to create a next-generation IVUS platform that addresses the needs of vascular interventionalists, and we are excited to launch Evident Vascular,” Vensana Capital Principal Cynthia Yee stated.
“Legacy IVUS platforms were originally designed primarily for coronary procedures and secondarily for peripheral vascular applications. Shortcomings in image quality, interpretation, and workflow have limited the widespread adoption of IVUS despite its clinical benefit, and there has been minimal innovation to address these limitations,” Evident Vascular Co-Founder/CEO Howard Rosen said. “Along with my co-founders, Chief Technology Officer Patrick Phillips, Ph.D., and Chief Product Officer Danielo Piazza, our team is pioneering the future of intravascular imaging with a platform optimized for peripheral vascular procedures that will enable improved image interpretation guidance, and ease of use enhancements throughout the clinical workflow.”
Evident Vascular is developing an advanced intravascular ultrasound (IVUS) platform technology designed initially for peripheral vascular interventions, with future capability for coronary procedures. Leveraging artificial intelligence (AI) to enable superior image interpretation and streamlined workflows, Evident Vascular’s technology has been designed to expand adoption of IVUS, driving increased market penetration and enabling improved clinical outcomes with faster, more accurate diagnosis and treatment decisions.
Vensana Capital is a venture capital and growth equity investment firm launched in 2019. Vensana manages $550 million in capital and is actively investing in developing and commercial stage companies across the medtech sector, including medical devices, diagnostics and data science, life science tools, digital health, and tech-enabled services. Vensana's investment team has a history of successfully partnering with management teams behind such companies as Cameron Health, CardiAQ, Cartiva, CV Ingenuity, Epix Therapeutics, Inari Medical, Intact Vascular, Lutonix, Neuwave Medical, Personal Genome Diagnostics, Relievant Medsystems, Sequent Medical, Topera, Ulthera, Veran Medical Technologies, Vertiflex, and Vesper Medical.
References
1 Centers for Medicare & Medicaid Services (CMS). Public Use Files (Medicare Claims) - Medicare Physician & Other Practitioners - by Geography and Service 2013-2020. Accessed May 2023.
2 Centers for Medicare & Medicaid Services (CMS). Standard Analytical Files (Medicare Claims) - LDS 2021. Accessed May 2023.
3 Healthcare Cost and Utilization Project (HCUP) National Inpatient Sample - 2017-2020. Accessed September 2022.